HK1206269A1 - Pharmaceutical formulation comprising bendamustine - Google Patents
Pharmaceutical formulation comprising bendamustineInfo
- Publication number
- HK1206269A1 HK1206269A1 HK15106962.4A HK15106962A HK1206269A1 HK 1206269 A1 HK1206269 A1 HK 1206269A1 HK 15106962 A HK15106962 A HK 15106962A HK 1206269 A1 HK1206269 A1 HK 1206269A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bendamustine
- pharmaceutical formulation
- formulation
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12160946.5A EP2641592A1 (en) | 2012-03-23 | 2012-03-23 | Pharmaceutical formulation comprising bendamustine |
PCT/EP2013/056213 WO2013139991A1 (en) | 2012-03-23 | 2013-03-25 | Pharmaceutical formulation comprising bendamustine |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1206269A1 true HK1206269A1 (en) | 2016-01-08 |
Family
ID=48087535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15106962.4A HK1206269A1 (en) | 2012-03-23 | 2015-07-21 | Pharmaceutical formulation comprising bendamustine |
Country Status (7)
Country | Link |
---|---|
US (1) | US20150050210A1 (ja) |
EP (2) | EP2641592A1 (ja) |
JP (1) | JP2015510920A (ja) |
AU (1) | AU2013237334A1 (ja) |
CA (1) | CA2865822A1 (ja) |
HK (1) | HK1206269A1 (ja) |
WO (1) | WO2013139991A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109953954A (zh) | 2013-08-27 | 2019-07-02 | V·沃道里斯 | 苯达莫司汀医药组合物 |
EP3116481A1 (en) | 2014-03-13 | 2017-01-18 | Vasilios VOUDOURIS | Bendamustine solid dispersions and continuous infusion |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007009242A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit magensaftresistenter Wirkstoff-Matix |
BRPI0922806B8 (pt) | 2008-12-03 | 2021-05-25 | Astellas Deutschland Gmbh | composição farmacêutica oral compreendendo bendamustina |
UA107186C2 (xx) | 2008-12-03 | 2014-12-10 | Тверді форми дозування бендамустину | |
CA2760085A1 (en) | 2009-04-28 | 2010-11-04 | Cephalon, Inc. | Oral formulations of bendamustine |
JO3659B1 (ar) | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
PT2575784T (pt) | 2010-06-02 | 2018-10-26 | Astellas Deutschland Gmbh | Formas de dosagem oral de bendamustina |
-
2012
- 2012-03-23 EP EP12160946.5A patent/EP2641592A1/en not_active Ceased
-
2013
- 2013-03-25 EP EP13715629.5A patent/EP2827844A1/en not_active Withdrawn
- 2013-03-25 WO PCT/EP2013/056213 patent/WO2013139991A1/en active Application Filing
- 2013-03-25 US US14/387,426 patent/US20150050210A1/en not_active Abandoned
- 2013-03-25 AU AU2013237334A patent/AU2013237334A1/en not_active Abandoned
- 2013-03-25 JP JP2015500950A patent/JP2015510920A/ja not_active Withdrawn
- 2013-03-25 CA CA2865822A patent/CA2865822A1/en not_active Abandoned
-
2015
- 2015-07-21 HK HK15106962.4A patent/HK1206269A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2015510920A (ja) | 2015-04-13 |
EP2641592A1 (en) | 2013-09-25 |
CA2865822A1 (en) | 2013-09-26 |
US20150050210A1 (en) | 2015-02-19 |
WO2013139991A1 (en) | 2013-09-26 |
AU2013237334A1 (en) | 2014-09-18 |
EP2827844A1 (en) | 2015-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2814487A4 (en) | BENDAMUSTIN FORMULATIONS | |
HUE064884T2 (hu) | Bendamusztin kiszerelések | |
HK1205146A1 (en) | Pharmaceutical formulation | |
HK1202445A1 (en) | New formulation | |
ZA201306000B (en) | Stable formulation | |
AP2015008208A0 (en) | Pharmaceutical administration forms comprising | |
HK1205683A1 (en) | Pharmaceutical formulation having improved stability | |
LT2934544T (lt) | Farmacinė kompozicija, apimanti ciklezonidą | |
EP2822599A4 (en) | VACCINE | |
ZA201601645B (en) | Bendamustine pharmaceutical compositions | |
HK1206269A1 (en) | Pharmaceutical formulation comprising bendamustine | |
HK1207296A1 (en) | Genotype- or phenotype-based drug formulation | |
SG11201406097SA (en) | Capsule formulation | |
LT2908836T (lt) | Farmacinė kompozicija, turinti kurkumino | |
HK1209339A1 (en) | Pharmaceutical formulations | |
HK1204945A1 (en) | Pharmaceutical formulation containing flupirtin | |
IL244316A0 (en) | A new composition of a drug | |
GB201211403D0 (en) | Pharmaceutical formulations | |
GB201211406D0 (en) | Pharmaceutical formulations | |
GB201204597D0 (en) | Topical pharmaceutical formulation | |
ECSP12011630A (es) | Formulación farmacéutica | |
GB201211247D0 (en) | Improved formulation |